Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 545 FIFTH AVENUE, SUITE 1400 NEW YORK NY 10017 |
Tel: | N/A |
Website: | https://www.appliedtherapeutics.com |
IR: | See website |
Key People | ||
Shoshana Shendelman Chairman of the Board, President, Chief Executive Officer, Founder | Leslie D. Funtleyder Chief Financial Officer and Principal Financial Officer, Director | Constantine Chinoporos Chief Operating Officer and Chief Business Officer |
Catherine Thorpe Chief Accounting Officer | Dale Hooks Chief Commercial Officer | Riccardo Perfetti Chief Medical Officer |
Business Overview |
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company's lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy. |
Financial Overview |
For the fiscal year ended 31 December 2023, Applied Therapeutics Inc revenues increased from $0K to $10M. Net loss increased 45% to $119.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Change in fair value of warrant liabilit increase from $66K to $56.6M (expense), Operating Lease Cost increase of 3% to $505K (expense). |
Employees: | 25 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $416.81M as of Dec 31, 2023 |
Annual revenue (TTM): | $9.99M as of Dec 31, 2023 |
EBITDA (TTM): | -$64.53M as of Dec 31, 2023 |
Net annual income (TTM): | -$119.76M as of Dec 31, 2023 |
Free cash flow (TTM): | -$55.17M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 105,886,831 as of Mar 5, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |